NasdaqCM:IMUX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Immunic's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IMUX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.2%

IMUX

6.0%

US Biotechs

1.0%

US Market


1 Year Return

27.7%

IMUX

30.5%

US Biotechs

13.6%

US Market

Return vs Industry: IMUX underperformed the US Biotechs industry which returned 31.5% over the past year.

Return vs Market: IMUX exceeded the US Market which returned 14.2% over the past year.


Shareholder returns

IMUXIndustryMarket
7 Day10.2%6.0%1.0%
30 Day-7.8%0.2%-0.4%
90 Day31.7%-1.8%8.9%
1 Year27.7%27.7%32.7%30.5%16.2%13.6%
3 Yearn/a18.6%12.8%40.2%30.8%
5 Yearn/a20.4%12.1%89.6%68.2%

Price Volatility Vs. Market

How volatile is Immunic's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Immunic undervalued compared to its fair value and its price relative to the market?

3.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IMUX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMUX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IMUX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMUX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMUX's PB Ratio (3.4x) is in line with the US Biotechs industry average.


Next Steps

Future Growth

How is Immunic forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

64.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMUX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMUX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMUX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if IMUX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if IMUX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMUX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Immunic performed over the past 5 years?

-54.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMUX is currently unprofitable.

Growing Profit Margin: IMUX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMUX is unprofitable, and losses have increased over the past 5 years at a rate of 54.1% per year.

Accelerating Growth: Unable to compare IMUX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMUX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: IMUX has a negative Return on Equity (-45.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is Immunic's financial position?


Financial Position Analysis

Short Term Liabilities: IMUX's short term assets ($53.0M) exceed its short term liabilities ($7.7M).

Long Term Liabilities: IMUX's short term assets ($53.0M) exceed its long term liabilities ($793.0K).


Debt to Equity History and Analysis

Debt Level: IMUX is debt free.

Reducing Debt: IMUX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMUX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if IMUX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Immunic current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMUX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMUX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMUX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMUX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMUX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Daniel Vitt (52 yo)

1.42yrs

Tenure

US$2,451,290

Compensation

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic AG since April 2019 and also its President. Dr. Vitt served as Managing Director of 4SC Discovery GmbH. Dr. Vitt Co-founded 4SC AG in No ...


CEO Compensation Analysis

Compensation vs Market: Daniel's total compensation ($USD2.45M) is about average for companies of similar size in the US market ($USD2.02M).

Compensation vs Earnings: Insufficient data to compare Daniel's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Duane Nash
Executive Chairman1.42yrsUS$1.27m0.048%
$ 179.5k
Daniel Vitt
CEO, President & Director1.42yrsUS$2.45m1.75%
$ 6.5m
Manfred Gröppel
Co-Founder & COOno dataUS$1.87m1.35%
$ 5.0m
Andreas Muehler
Chief Medical Officerno dataUS$2.12mno data
Glenn Whaley
VP of Finance and Principal Financial & Accounting Officer0.42yrno data0.0048%
$ 17.9k
Hella Kohlhof
Chief Scientific Officer3.67yrsno data0.048%
$ 178.9k
Jessica Breu
Manager of IR & Communicationsno datano datano data

0.9yrs

Average Tenure

51.5yo

Average Age

Experienced Management: IMUX's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Duane Nash
Executive Chairman1.42yrsUS$1.27m0.048%
$ 179.5k
Daniel Vitt
CEO, President & Director1.42yrsUS$2.45m1.75%
$ 6.5m
Barclay Phillips
Independent Director0.83yrUS$158.79k0%
$ 0
Tamar Howson
Independent Director0.92yrUS$194.69k0%
$ 0
Jörg Neermann
Independent Director1.42yrsUS$304.04k0%
$ 0
Vincent Ossipow
Independent Director1.42yrsUS$303.42k0%
$ 0
Jan Van den Bossche
Independent Director1.42yrsUS$305.22k0%
$ 0

1.4yrs

Average Tenure

52yo

Average Age

Experienced Board: IMUX's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IMUX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 105.3%.


Top Shareholders

Company Information

Immunic, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immunic, Inc.
  • Ticker: IMUX
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$370.651m
  • Shares outstanding: 20.72m
  • Website: https://www.immunic-therapeutics.com

Number of Employees


Location

  • Immunic, Inc.
  • 11440 West Bernardo Court
  • Suite 300
  • San Diego
  • California
  • 92127
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMUXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2019
10VADB (Deutsche Boerse AG)YesCommon StockDEEURApr 2019

Biography

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative coliti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 06:25
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.